Table 4.
Summary of recurrence and long-term survival.
| Author | Group | Follow-up | R | Survival (time: month; rate: %) |
|---|---|---|---|---|
| Tranchart et al. | LH | 29.7 | 10 | 1, 3, 5 y-DFS: 81.6, 60.9, 45.6; 1, 3, 5 y-OS: 93.1, 74.4, 59.5. |
| OH | 24.6 | 12 | 1, 3, 5 y-DFS: 70.2, 54.3, 37.2; 1, 3, 5 y-OS: 81.8, 73, 47.4. | |
| Kim et al. | LH | 21.8 | 7 | MDFS: 13.4; 1 y-DFS: 84.6. |
| OH | 24.8 | 10 | MDFS: 14.6; 1 y-DFS: 82.8. | |
| Truant et al. | LH | 35.7 | 16 | 5 y-DFS: 35.5; 5 y-OS: 70. |
| OH | 23 | 5 y-DFS: 33.6; 5 y-OS: 46. | ||
| Lee et al. | LH | 35.4 | 15 | 1, 3, 5 y-DFS: 78.8, 51, 45.3; 1, 3, 5 y-OS: 86.9, 81.8, 76.0. |
| OH | 28.5 | 19 | 1, 3, 5 y-DFS: 69.2, 55.9, 55.9; 1, 3, 5 y-OS: 98, 80.6, 76.1. | |
| Ahn et al. | LH | 38.6 | 12 | 5 y-DFS: 67.8; 5 y-OS: 80.1. |
| OH | 52.3 | 21 | 5 y-DFS: 54.8; 5 y-OS: 85.7. | |
| Kim et al. | LH | 47.9 | 11 | MDFS: 15.4; MOS: 47.9; 1, 3, 5 y-DFS: 81.1, 61.7, 54.0; 1, 3, 5 y-OS: 100, 100, 92.2. |
| OH | 59.5 | 16 | MDFS: 32.6; MOS: 59.5; 1, 3, 5 y-DFS: 78.6, 60.9, 40.1; 1, 3, 5 y-OS: 96.5, 92.2, 87.7. | |
| Memeo et al. | LH | NR | 25 | 1, 5, 10 y-DFS: 80, 19, 0; 1, 5, 10 y-OS: 88, 59, 12. |
| OH | NR | 28 | 1, 5, 10 y-DFS: 60, 23, 9; 1, 5, 10 y-OS: 63, 44, 22. | |
| Lee et al. | LH | 22.7 | NR | 1, 3, 5 y-DFS: 60.5, 53.5, 53.5; 1, 3, 5 y-OS: 95.3, 89.7, 89.7. |
| OH | 44.4 | NR | 1, 3, 5 y-DFS: 81.5, 66.7, 58.6; 1, 3, 5 y-OS: 93.9, 89.5, 87.3. | |
| Luo et al. | LH | 35 | 20 | MDFS: 21. |
| OH | 37 | 24 | MDFS: 18. | |
| Takahara et al. | LH | 46.7 | NR | 1, 3, 5 y-DFS: 83.7, 58.3, 40.7; 1, 3, 5 y-OS: 95.8, 86.2, 76.8. |
| OH | 51.7 | NR | 1, 3, 5 y-DFS: 79.6, 50.4, 39.3; 1, 3, 5 y-OS: 95.8, 84.0, 70.9. | |
| Han et al. | LH | 44.0 | 43 | 1, 3, 5 y-DFS: 69.7, 52.0, 44.2; 1, 3, 5 y-OS: 91.6, 87.5, 76.4. |
| OH | 48.7 | 46 | 1, 3, 5 y-DFS: 74.7, 49.5, 41.2; 1, 3, 5 y-OS: 93.1, 87.8, 73.2. | |
| Yoon et al. | LH | NR | 16 | 1, 2, 3, 4 y-DFS: 82.0, 63.0, 56.0, 56.0; 1, 2, 3, 4 y-OS: 95.0, 92.0, 86.0, 86.0. |
| OH | NR | 31 | 1, 2, 3, 4 y-DFS: 88.0, 79.0, 62.0, 62.0; 1, 2, 3, 4 y-OS: 98.0, 93.0, 84.0, 68.0. | |
| Cheung et al. | LH | 34.6 | 36 | MDFS: 66.4; MOS: 136; 1, 3, 5 y-DFS: 87.7, 65.8, 52.2; 1, 3, 5 y-OS: 98.9, 89.8, 83.7. |
| OH | 46.6 | 160 | MDFS: 52.4; MOS: 120; 1, 3, 5 y-DFS: 75.2, 56.3, 47.9; 1, 3, 5 y-OS: 94, 79.3, and 67.4. | |
| Sposito et al. | LH | 39.3 | NR | MDFS: 25.5; MOS: 48.8; 3, 5 y-DFS: 41, 25; 3, 5 y-OS: 75, 38. |
| OH | 44.5 | NR | MDFS: 31.7; MOS: 57.8; 3, 5 y-DFS: 44, 11; 3, 5 y-OS: 79, 46. | |
| Jiang et al. | LH | NR | 26 | MDFS: 17; 5 y-DFS: 44. |
| OH | NR | 30 | MDFS: 15; 5 y-DFS: 40. | |
| Komatsu et al. | LH | 24.7 | NR | 3 y-DFS: 50.3; 3 y-OS: 73.4. |
| OH | NR | 3 y-DFS: 29.7; 3 y-OS: 69.2. | ||
| Yoon et al. | LH | NR | NR | 2 y-DFS: 85.1; 2 y-OS: 100. |
| OH | NR | NR | 2 y-DFS: 83.9; 2 y-OS: 88.8. | |
| Xu et al. | LH | 13.8 | NR | 1, 2 y-DFS: 95.5, 72.9; 1, 2 y-OS: 100, 85.7. |
| OH | NR | 1, 2 y-DFS: 93.5, 81.5; 1, 2 y-OS: 96.3, 86.7. |
Follow-up was shown as median month; R: recurrence; DFS: disease-free survival rate; OS: overall survival rate; MDFS: median disease-free survival time; MOS: median overall survival time; y: year; NR: not reported.